|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
CTG008525382 |
| 003 |
DE-627 |
| 005 |
20230425182207.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
220628s2022 xx |||||o 00| ||eng c |
| 035 |
|
|
|a (DE-627)CTG008525382
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)ISRCTN70794078
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)2021-004021-71
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)Nil known
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 245 |
1 |
0 |
|a Prednisolone for loss of smell after COVID-19 infection
|b COrticosteroids for COVID-19 induced loss of Smell (COCOS trial)
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 09-06-2022, Last updated: 2022-12-02
|
| 650 |
|
4 |
|a Medical Condition: Persistent (>1 month) loss of smell within 3 months of COVID-19 (SARS-CoV-2 infection) diagnosis based on a positive test Infections and Infestations
|
| 650 |
|
4 |
|a Study Type: Interventional
|
| 650 |
|
4 |
|a Phase: Phase 4
|
| 650 |
|
4 |
|a Recruitment Status: Recruiting
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2022) vom: 28. Nov.
|
| 773 |
1 |
8 |
|g year:2022
|g day:28
|g month:11
|
| 856 |
4 |
0 |
|u https://www.isrctn.com/ISRCTN70794078
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2022
|b 28
|c 11
|
Klinische Studie